Midazolam detected after a fatal crash does not, by itself, establish that the person took it before the collision. In a Milan autopsy review, investigators attributed midazolam findings in two crash cases to hospital treatment; one also had ketamine detected. The timing and source of exposure had to be interpreted through treatment records and circumstances.
What the crash cases actually showed
Di Candia and colleagues reviewed 136 cases referred for toxicological analysis among 1,323 autopsies during 2018–2019. Thirteen people in the reviewed series died following car accidents. Seven had negative toxicological findings, and four had ethanol concentrations reported between 0.83 and 1.38 g/L.
The remaining two cases involved midazolam. One was a male in the 21–30-year age category, identified as case 7. Another, case 123, had both midazolam and ketamine. The authors explained those findings by hospital administration for sedation and severe pain in the polytrauma setting.
This was a retrospective interpretation of two cases within a broader series, not a prospective trial of emergency treatment. It did not estimate how frequently all fatal-crash toxicology findings arise from medical administration.
The specimen did not timestamp administration
Biological samples were collected at autopsy and stored at −20°C. Femoral and cardiac blood, urine and gastric contents were the principal matrices across the study, with selected organs analyzed when needed. The investigators used HPLC–MS/MS and GC–MS, as well as headspace methods for alcohol and volatile substances.
Table 1 reports one car-accident midazolam finding at 0.09 µg/mL in cardiac blood and 0.08 µg/mL in femoral blood. Those are measurements in two postmortem specimens. Their similarity did not establish whether administration preceded the crash, followed rescue, or occurred during subsequent hospital treatment.
The main report did not provide the precise dosing and treatment-to-death timeline for these crash examples. It therefore supplies no validated concentration-to-administration-time conversion or estimate of a precrash dose.
Analytical identity and exposure provenance are different questions
The laboratory workflow moved from screening to further qualitative identification and, where confirmed, calibration-based quantification. Identifying a substance answers whether the analytical evidence supports its presence in that specimen.
Determining why it was present requires a separate timeline. Medication charts, emergency records, documented procedures and specimen collection times can place a detected drug within treatment. A concentration alone cannot replace that history.
Similarly, detecting both a sedative and another drug does not prove a precrash recreational combination. In these cases the authors considered hospital administration the explanation; their attribution should not be rewritten as independent proof of earlier self-administration.
What cannot be inferred about driving or causation
The series did not measure driving performance before the collision or demonstrate that midazolam caused either crash. A drug can be detected after treatment without having contributed to the event that required treatment.
The study’s interpretation also does not make every postmortem midazolam result automatically therapeutic. The relevant conclusion depends on evidence from the individual case. Treatment attribution in these two cases cannot be generalized to a person with different records or circumstances.
A useful way to read the report
Keep the analytical result, specimen site and unit alongside the exposure timeline. Identify which findings are measured and which are inferred from records. Preserve any missing administration details rather than filling them with a guessed dose or time.
These distinctions are relevant whenever hospital care precedes death. For another specimen-related complication in that setting, see hospital ethanol specimens and differences between serum and whole blood.
Primary source
Di Candia D, Giordano G, Boracchi M, Zoja R. Postmortem forensic toxicology cases: A retrospective review from Milan, Italy. Journal of Forensic Sciences. 2022;67:1640–1650. doi:10.1111/1556-4029.15050.
Leave a Reply